News happening at Kenox

Pharmaceutical industry veteran Dr. Nuggehally Srinivas joins Kenox executive team

06 January 2020 , Princeton, NJ

Kenox Pharmaceuticals Inc. (Kenox), a speciality  pharmaceutical company in aerosol drug delivery.Today announced the appointment of Dr Nuggehally Srinivas to the role of Chief Operating Officer. With extensive scientific, management and operational experience for nearly 30 years, Dr. Srinivas further strengthens the Kenox leadership team during the initial period of rapid growth in the innovative and specialty product space. As COO, Dr. Srinivas will lead Scientific, Strategic and Business initiatives for the continued growth of Kenox.

“Dr. Srinivas joins Kenox at an appropriate time with a strong drug development including regulatory and clinical experience in innovative and specialty products using 505(b)(2) related pathway,” commented Dr Sitaram Velaga, Kenox’s CEO and Founder. Also, Dr. Sitaram said “We are delighted to have on board a thought leader in creating new strategies and business models as we embark our journey to build rich pipeline drugs with diverse aerosol delivery platforms for variety of indications.”

Dr. Srinivas started his career at Bristol-Myers Squibb (Syracuse & Princeton, USA) and for over a decade he was involved in multiple INDs, preclinical and clinical pharmacology activities of diverse therapeutic programs with successful NDAs. Following which he spent over 6 years at Reddy’s Laboratories where he was responsible for drug candidate nomination, preclinical and clinical drug development of novel drug assets in diabetes, metabolic disorders, cardiovascular, inflammation, oncology and anti-infective programs. Dr. Srinivas had an entrepreneurial stint for 1.5 years setting up a virtual oncology drug development with acquired assets from academia, biotechs and Pharmacos. As the CSO/CEO of Vanthys Pharmaceuticals Pvt Ltd (JV between Eli Lilly and Jubilant Life Sciences) for nearly 4 years, he led scientific/medical/regulatory teams for successful human POC decisions for a number of Eli Lilly’s and Jubilant drug discovery assets.

In the tenure as a consultant for about 3.5 years, Dr. Srinivas helped Biotechs, Generic and Specialty players to make product decisions using clinical pharmacology and PKPD attributes with regulatory and clinical inputs for 505(b)(1) & (b)(2) and complex generic drug developments. In his tenure at Zydus Cadila for over 2.5 years, Dr. Srinivas was involved in NCE, Biosimilar and specialty product development. In his most recent position, Dr Srinivas was involved in putting a framework, strategy and ideation tools for the development of innovative products at Jubilant Life Sciences.